Navigation Links
Therapy slows onset and progression of Lou Gehrig's disease, study finds
Date:9/9/2013

nd in many patients with familial ALS, which accounts for about 2 percent of all cases.

SOD1 provides instructions for making an enzyme called superoxide dismutase, which is found throughout the body and breaks down toxic molecules that can be damaging to cells. When mutated, the SOD1 gene yields a faulty version of the enzyme that is especially harmful to motor neurons. One of the mutations, which is found in about half of all familial ALS patients, is particularly devastating, with death usually coming within 18 months of diagnosis. SOD1 has also been implicated in other types of ALS, called sporadic ALS, which means the therapy could prove beneficial for larger numbers of patients suffering with this disease.

Earlier work by Dr. Kaspar and others found that they could halt production of the mutated enzyme by blocking SOD1 expression, which in turn, they suspected, would slow ALS progression. To test this hypothesis, the researchers would not only need to come up with an approach that would block the gene, but also figure out how to specifically target cells implicated in the disease, which include motor neurons and glial cells. What's more, the therapy would preferably be administered noninvasively instead of direct delivery via burr holes drilled into the skull.

Dr. Kaspar's team accomplished the second part of this challenge in 2009, when they discovered that adeno-associated virus serotype 9 (AAV9) could cross the blood-brain barrier, making it an ideal transport system for delivering genes and RNA interference strategies designed to treat disease.

In this new work, funded by the National Institutes of Health, the researchers blocked human SOD1, using a technology known as short hairpin RNA, or shRNA. These single strands of RNA are designed in the lab to seek out specific sequences found in the human SOD1 gene, latch onto them and block gene expression.

In one of the mouse models used in the study, ALS develops
'/>"/>

Contact: Gina Bericchia
Gina.Bericchia@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Physiotherapy in Singapore Clinic Urbanrehab Pte Ltd Announces the Opening of an Additional Location
2. Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
3. ITN type 1 diabetes study identifies subset of patients with strong response to therapy
4. Combined therapy could repair and prevent damage in Duchenne muscular dystrophy
5. Study suggests way to fight therapy resistant leukemia by blocking DNA repair
6. An effective initial polytherapy for infantile spasms
7. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
8. Neuroblastoma: Autophagy protects from chemotherapy
9. Dendritic cell therapy improves kidney transplant survival, Pitt team says
10. No danger of cancer through gene therapy virus
11. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... of the environmental effects of moorland burning is published ... subject, with the aim of relieving tensions on both ... The EMBER (Effects of Moorland Burning on the Ecohydrology ... on moorland, which is practised predominantly to support red ... on peat hydrology, peat chemistry and physical properties, river ...
(Date:9/30/2014)... comprehensive assessment conducted by the Ocean Health Index ... 100 in overall health. In addition, for the ... the 15 ocean regions beyond national jurisdiction (high-seas ... healthy climate, safeguarding biodiversity and providing sustainable food ... the index, a partnership led by scientists from ...
(Date:9/30/2014)... The National Institutes of Health (NIH) awarded Lawrence ... develop an electrode array system that will enable ... through unprecedented resolution and scale. , LLNL,s grant-funded ... President Obama,s BRAIN (Brain Research through Advancing ... to revolutionize our understanding of the human mind ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Rating the planet's oceans 2Rating the planet's oceans 3NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... of modern-day birds took to the skies by gliding ... and legs, according to new research by a University ... journal Paleobiology, Department of Biological Sciences PhD student Nick ... taking off from the ground while running and shows ...
... role in mediating the outcome of competition between rival ... in the New World--or, on a much smaller ecological ... to competing bacteria. In a new study, researchers have ... with one another, and they have found that each ...
... directly comparing weight-loss outcomes in super-obese patients, researchers ... newer operation, the duodenal switch, produced substantially better ... gastric bypass. , In the October issue of ... the duodenal switch (DS) produced greater weight loss ...
Cached Biology News:Ancient birds flew on all-fours 2Different strategies underlie the ecology of microbial invasions 2For super-obese patients, duodenal switch beats gastric bypass 2For super-obese patients, duodenal switch beats gastric bypass 3
(Date:9/30/2014)... Over the last decade, the laboratory filtration market ... and increased acceptance of new filtration technologies in end ... are also catalyzing the growth of laboratory filtration market. ... grow at a strong CAGR during the forecast period ... million by 2019. The market is mainly driven by ...
(Date:9/30/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the ... received a Canadian Patent for Inhibition or Reversal ... includes claims using thymosin beta 4, various fragments ... these purposes.  The patent will expire in 2021. ... www.regenerx.com ) RegeneRx is focused ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)... BioHealth Innovation, Inc. (BHI), a ... and increasing access to early-stage funding in ... Tania Fernandez , Ph.D., has joined the BHI ... a member of the management team for a new ... million in seed and early-stage equity investments to therapeutics, ...
Breaking Biology Technology:Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced today that it ... Equity Conference to be held August,18-19, 2008 at the ... of Access is scheduled to speak on Monday, August ... and will give a corporate overview and,discuss the Company,s ...
... Anthera Pharmaceuticals,Inc., a privately held biopharmaceutical company ... a $19 Million,equity financing. New investors Caxton ... HBM BioCapital (Cayman Islands) led the financing, ... Advantage Venture Partners (the,General Partner of Caxton ...
... MS, EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced financial and ... 2008. BioMS Medical, in partnership with Eli Lilly ... for the treatment of MS,undergoing pivotal trials in ...
Cached Biology Technology:Access Pharmaceuticals to Present at the Noble Financial Equity Conference 2Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman 2Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman 3BioMS Medical Announces Second Quarter 2008 Results 2BioMS Medical Announces Second Quarter 2008 Results 3BioMS Medical Announces Second Quarter 2008 Results 4BioMS Medical Announces Second Quarter 2008 Results 5